CEL-SCI TO PRESENT AT 18TH ANNUAL BIO CEO & INVESTOR CONFERENCE

Vienna, VA, February 3, 2016 -- CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 11:00 a.m. Hosted by the Biotechnology Industry Organization (BIO), the 18th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf Astoria in New York City.

A live audio webcast of the presentation and replay will be available under the investor relations section of CEL-SCI's website at www.cel-sci.com/investor_relations.html. The replay of the presentation will be available approximately 1 hour after the presentation and is accessible until May 8, 2016.

About the BIO CEO & Investor Conference

Now in its eighteenth year, the BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Each year this conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

About CEL-SCI Corporation

CEL-SCI is a Phase 3 immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. We believe that one must activate the immune system BEFORE radiation and chemotherapy, and even before surgery, to achieve the best results in the greatest number of patients. CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine (Leukocyte Interleukin Injection) for the treatment of head and neck cancer, which accounts for about 6% of cancers globally and a $6 billion market. Almost 700 patients are already enrolled in this study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV infected patients with HPV related diseases. CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its own 75,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. When fully built out, this facility will have the capacity to supply about $3 billion worth of Multikine annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology as a potential vaccine for the treatment of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.